Gonadotropin-releasing hormone antagonist: how good is the new hope?
- 1 June 2001
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 13 (3) , 257-262
- https://doi.org/10.1097/00001703-200106000-00002
Abstract
Gonadotropin-releasing hormone agonists have been widely used to prevent luteinizing hormone surges during controlled ovarian stimulation in assisted reproductive technologies. Treatment with gonadotropin-releasing hormone agonists of uterine myoma, endometriosis and some hormone-dependent cancers, such as breast, ovarian, endometrial and prostate cancer, also seems to have a beneficial effect. Gonadotropin-releasing hormone agonists have the disadvantage of inducing an initial stimulatory effect on gonadotropin secretion, necessitating 2-3 weeks before pituitary desensitization is achieved. Gonadotropin-releasing hormone antagonists, on the contrary, cause an immediate inhibition of gonadotropin secretion by competitive blocking of pituitary gonadotropin-releasing hormone receptors. Some advantages of their clinical use in controlled ovarian stimulation have already been demonstrated. Randomized comparative studies are needed to investigate their benefit over gonadotropin-releasing hormone antagonists for myoma and hormone-related disorders.Keywords
This publication has 39 references indexed in Scilit:
- Luteinizing Hormone–Releasing Hormone Agonist Triptorelin and Antagonist Cetrorelix Inhibit EGF-Induced c-fos Expression in Human Gynecological CancersGynecologic Oncology, 2000
- Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145Journal of Clinical Endocrinology & Metabolism, 1996
- Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancerThe Prostate, 1994
- High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell linesJournal of Clinical Endocrinology & Metabolism, 1993
- Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaPJournal of Clinical Endocrinology & Metabolism, 1992
- Gonadotropin-releasing hormone specific binding sites in uterine leiomyomataBiochemical and Biophysical Research Communications, 1988
- Clinical aspects with regard to the occurrence of an endogenous luteinizing hormone surge in gonadotropin-induced normal menstrual cyclesJournal of Assisted Reproduction and Genetics, 1986
- Reproductive/endocrine and anaphylactoid properties of an LHRH-antagonist, ORF 18260 [Ac-DNAL1(2),4FDPhe2,D-Trp3,D-Arg6]-GnRHLife Sciences, 1985
- Reduced in‐vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phaseBJOG: An International Journal of Obstetrics and Gynaecology, 1985
- Pregnancies in Humans by Fertilization in Vitro and Embryo Transfer in the Controlled Ovulatory CycleScience, 1981